Literature DB >> 24959965

The arrival of untreatable multidrug-resistant HIV-1 in sub-Saharan Africa.

Brian Magambo1, Jamirah Nazziwa, Nicholas Bbosa, Ravindra K Gupta, Pontiano Kaleebu, Chris M Parry.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24959965     DOI： 10.1097/QAD.0000000000000216

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  5 in total

1.  HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya.

Authors:  Rami Kantor; Allison DeLong; Leeann Schreier; Marissa Reitsma; Emanuel Kemboi; Millicent Orido; Salome Obonge; Robert Boinett; Mary Rono; Wilfred Emonyi; Katie Brooks; Mia Coetzer; Nathan Buziba; Joseph Hogan; Lameck Diero
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

Review 2.  Development of Protein-Protein Interaction Inhibitors for the Treatment of Infectious Diseases.

Authors:  Andrew F Voter; James L Keck
Journal:  Adv Protein Chem Struct Biol       Date:  2017-08-24       Impact factor: 3.507

3.  Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study.

Authors:  Graeme Meintjes; Liezl Dunn; Marla Coetsee; Michael Hislop; Rory Leisegang; Leon Regensberg; Gary Maartens
Journal:  AIDS Res Ther       Date:  2015-12-01       Impact factor: 2.250

4.  A retrospective descriptive investigation of adult patients receiving third-line antiretroviral therapy in the North West province, South Africa.

Authors:  Christian Rudman; Michelle Viljoen; Malie Rheeders
Journal:  Afr Health Sci       Date:  2020-06       Impact factor: 0.927

5.  Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes.

Authors:  Michelle Moorhouse; Gary Maartens; Willem Daniel Francois Venter; Mahomed-Yunus Moosa; Kim Steegen; Khadija Jamaloodien; Matthew P Fox; Francesca Conradie
Journal:  J Acquir Immune Defic Syndr       Date:  2019-01-01       Impact factor: 3.731
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.